Mossmann D, Park S, Hall MN. mTOR signalling and cellular metabolism are mutual determinants in cancer. Nat Rev Cancer. 2018;18:744–57.

Article  CAS  PubMed  Google Scholar 

Panwar V, Singh A, Bhatt M, Tonk RK, Azizov S, Raza AS, et al. Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease. Signal Transduct Target Ther. 2023;8:375.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168:960–76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kwiatkowski DJ, Zhang H, Bandura JL, Heiberger KM, Glogauer M, El-Hashemite N, et al. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum Mol Genet. 2002;11:525–34.

Article  CAS  PubMed  Google Scholar 

Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell. 2002;10:151–62.

Article  CAS  PubMed  Google Scholar 

Potter CJ, Pedraza LG, Xu T. Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol. 2002;4:658–65.

Article  CAS  PubMed  Google Scholar 

Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol. 2002;4:648–57.

Article  CAS  PubMed  Google Scholar 

Gao X, Zhang Y, Arrazola P, Hino O, Kobayashi T, Yeung RS, et al. Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat Cell Biol. 2002;4:699–704.

Article  CAS  PubMed  Google Scholar 

Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008;358:140–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011;364:1595–606.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang H, Bajraszewski N, Wu E, Wang H, Moseman AP, Dabora SL, et al. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest. 2007;117:730–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jahn SC, Law ME, Corsino PE, Davis BJ, Harrison JK, Law BK. Signaling mechanisms that suppress the cytostatic actions of rapamycin. PLoS ONE. 2014;9:e99927.

Article  PubMed  PubMed Central  Google Scholar 

Lu Y, Zhang EY, Liu J, Yu JJ. Inhibition of the mechanistic target of rapamycin induces cell survival via MAPK in tuberous sclerosis complex. Orphanet J Rare Dis. 2020;15:209.

Article  PubMed  PubMed Central  Google Scholar 

Fonseca BD, Smith EM, Lee VH, MacKintosh C, Proud CG. PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex. J Biol Chem. 2007;282:24514–24.

Article  CAS  PubMed  Google Scholar 

Oshiro N, Takahashi R, Yoshino K, Tanimura K, Nakashima A, Eguchi S, et al. The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. J Biol Chem. 2007;282:20329–39.

Article  CAS  PubMed  Google Scholar 

Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, Spooner E, et al. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell. 2007;25:903–15.

Article  CAS  PubMed  Google Scholar 

Vander Haar E, Lee SI, Bandhakavi S, Griffin TJ, Kim DH. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol. 2007;9:316–23.

Article  CAS  PubMed  Google Scholar 

Wang L, Harris TE, Roth RA, Lawrence JC Jr. PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J Biol Chem. 2007;282:20036–44.

Article  CAS  PubMed  Google Scholar 

Gai X, Tang B, Liu F, Wu Y, Wang F, Jing Y, et al. mTOR/miR-145-regulated exosomal GOLM1 promotes hepatocellular carcinoma through augmented GSK-3beta/MMPs. J Genet Genomics. 2019;46:235–45.

Article  CAS  PubMed  Google Scholar 

Liko D, Rzepiela A, Vukojevic V, Zavolan M, Hall MN. Loss of TSC complex enhances gluconeogenesis via upregulation of Dlk1-Dio3 locus miRNAs. Proc Natl Acad Sci USA. 2020;117:1524–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun W, Shen W, Yang S, Hu F, Li H, Zhu TH. miR-223 and miR-142 attenuate hematopoietic cell proliferation, and miR-223 positively regulates miR-142 through LMO2 isoforms and CEBP-beta. Cell Res. 2010;20:1158–69.

Article  PubMed  Google Scholar 

Isobe T, Hisamori S, Hogan DJ, Zabala M, Hendrickson DG, Dalerba P, et al. miR-142 regulates the tumorigenicity of human breast cancer stem cells through the canonical WNT signaling pathway. Elife. 2014. https://doi.org/10.7554/eLife.01977.

Article  PubMed  PubMed Central  Google Scholar 

Li Y, He Q, Wen X, Hong X, Yang X, Tang X, et al. EZH2-DNMT1-mediated epigenetic silencing of miR-142-3p promotes metastasis through targeting ZEB2 in nasopharyngeal carcinoma. Cell Death Differ. 2019;26:1089–106.

Article  CAS  PubMed  Google Scholar 

Trelinska J, Fendler W, Dachowska I, Kotulska K, Jozwiak S, Antosik K, et al. Abnormal serum microRNA profiles in tuberous sclerosis are normalized during treatment with everolimus: possible clinical implications. Orphanet J Rare Dis. 2016;11:129.

Article  PubMed  PubMed Central  Google Scholar 

Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307:1098–101.

Article  CAS  PubMed  Google Scholar 

Huang L, Nakai Y, Kuwahara I, Matsumoto K. PRAS40 is a functionally critical target for EWS repression in Ewing sarcoma. Cancer Res. 2012;72:1260–9.

Article  CAS  PubMed  Google Scholar 

Ren S, Luo Y, Chen H, Warburton D, Lam HC, Wang LL, et al. Inactivation of Tsc2 in mesoderm-derived cells causes polycystic kidney lesions and impairs lung alveolarization. Am J Pathol. 2016;186:3261–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Drusian L, Nigro EA, Mannella V, Pagliarini R, Pema M, Costa ASH, et al. mTORC1 upregulation leads to accumulation of the oncometabolite fumarate in a mouse model of renal cell carcinoma. Cell Rep. 2018;24(1093–104):e6.

Google Scholar 

Bonucci M, Kuperwasser N, Barbe S, Koka V, de Villeneuve D, Zhang C, et al. mTOR and S6K1 drive polycystic kidney by the control of Afadin-dependent oriented cell division. Nat Commun. 2020;11:3200.

Article  PubMed  PubMed Central  Google Scholar 

Pema M, Drusian L, Chiaravalli M, Castelli M, Yao Q, Ricciardi S, et al. mTORC1-mediated inhibition of polycystin-1 expression drives renal cyst formation in tuberous sclerosis complex. Nat Commun. 2016;7:10786.

Article  CAS